ProofPilot has announced a strategic collaboration with Eli Lilly and Company (Lilly) to offer Lilly's patent-pending, sensor cloud platform, Magnol.AI™, a platform that enables management of high-frequency sensor data with security, as part of ProofPilot's technology solution.
For the first time, Lilly is out-licensing its technology. This technology-focused collaboration with Lilly and ProofPilot will enable both companies to help the broader research community to execute digital health research, helping to accelerate pre-competitive biomedical research.
"We are thrilled to collaborate with Lilly and leverage its industry-leading sensor cloud, further strengthening our commitment to provide our customers with the most advanced solutions and enable flawless execution of clinical research" said Chris Venezia, CEO of ProofPilot in a press release. "By integrating Magnol.AI™ into our platform, researchers finally have a one-stop, comprehensive solution to execute digital health research and deliver sensor data-driven insight with the highest quality."
Magnol.AI™ is Lilly's sensor cloud platform that allows for ingestion, visualization, and extraction of high-frequency sensor data with security. It is able to ingest and align a wide array of raw data from wearables, devices, and beyond in a clear time-series format. When aligned with clinician and patient reported outcomes, Magnol.AI™ enables real-time data science capabilities for digital health and digital biomarker research.
ProofPilot's mission is to perfect clinical research execution by orchestrating technology, tasks, content, and communication through its clinical trial automation platform. When combined with Lilly's sensor cloud Magnol.AI™, ProofPilot delivers a data science solution to digital health and digital biomarker researchers around the world. With this new integration, any researcher can now have access to a digital health research platform that combines data collection, sensor ingestion, device management, and participant engagement.
ProofPilot To Integrate Lilly's Magnol.AI™ Sensor Cloud Into Its Clinical Trial Automation Platform. (2023, September 28). Cision PR Newswire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.